Blood & Lymphoreticular

Acute promyelocytic leukemia: recognition and management

Clinical Overview and When to Suspect APL

— New pancytopenia or bicytopenia with bleeding out of proportion to platelet count (gum bleeding, epistaxis, menorrhagia, intracranial hemorrhage, oozing from venipuncture).

— Spontaneous bruising + fatigue + fever in a previously healthy young/middle-aged adult.

— Lab combo: anemia + thrombocytopenia + prolonged PT/PTT + low fibrinogen + elevated D-dimer.

— Peripheral smear with hypergranular promyelocytes, bilobed "butterfly" nuclei, Auer rods, faggot cells.

— Variant microgranular (M3v) form: high WBC, scant granules — easy to miss.

Acute promyelocytic leukemia (APL) is the M3 subtype of AML, defined by the t(15;17)(q24;q21) PML-RARA fusion, which arrests myeloid differentiation at the promyelocyte stage.

Accounts for ~10–15% of adult AML; median age ~40 years (younger than typical AML), with higher incidence in Hispanic/Latino populations.

True hematologic emergency — untreated early death from coagulopathy (DIC + hyperfibrinolysis) can occur within hours to days, before any cytogenetic confirmation.

When to suspect in the ED:

Board pearl: APL is the only AML subtype where the diagnosis itself triggers immediate empiric therapy with ATRA before genetic confirmation returns — because the killer is coagulopathy, not leukemic burden.

Step 3 management trigger: any AML-suspicious smear with coagulopathy or DIC labs → start all-trans retinoic acid (ATRA) 45 mg/m²/day PO divided BID immediately, aggressively transfuse, send PML-RARA PCR/FISH, admit to a center capable of hematology/oncology care.

Mortality is bimodal: very high in the first 30 days (hemorrhage), then >90% cure if patients survive induction — making early ED recognition the single highest-leverage intervention in all of acute leukemia care.

Presentation Patterns and Key History

— Bleeding: gingival bleeding while brushing, recurrent epistaxis, menorrhagia, easy bruising, prolonged bleeding from minor cuts, hematuria, melena, hemoptysis.

— Anemia symptoms: fatigue, exertional dyspnea, palpitations, lightheadedness, pallor noted by family.

— Infection: low-grade fevers, recurrent URIs, oral ulcers, perirectal pain (think neutropenia even before counts return).

— CNS red flags: headache, vision change, focal deficits, altered mental status → suspect intracranial hemorrhage (the #1 cause of induction death in APL).

— Prior chemotherapy with topoisomerase II inhibitors (etoposide, anthracyclines) — therapy-related APL, often 1–3 years after exposure (e.g., prior breast cancer treatment).

— Obesity (modest association); no strong familial pattern.

— Unlike other AMLs, myelodysplastic prodrome is uncommon — patients often feel well until weeks before diagnosis.

— Anticoagulants/antiplatelets — amplify bleeding risk.

— NSAID use — may worsen mucosal bleeding.

— Pregnancy status in reproductive-age women (changes ATRA timing — ATRA is teratogenic, category D).

APL typically presents subacutely over 2–4 weeks with cytopenia symptoms, but the bleeding tempo can accelerate suddenly.

Classic history elements to elicit:

Risk factors / associations:

Medication and social history that matter:

Key distinction: A young adult with pancytopenia + DIC + no sepsis source is APL until proven otherwise — sepsis-driven DIC usually has an obvious infectious driver; APL's DIC is intrinsic to the disease (promyelocyte granules release tissue factor and annexin II–mediated plasminogen activation).

Board pearl: Ask specifically about headache and visual changes — a "headache + low platelets + abnormal coags" trio in a leukemia workup should prompt emergent non-contrast head CT before lumbar puncture or sedation, and before any invasive line placement when avoidable.

Physical Exam Findings and Hemodynamic Assessment

— Tachycardia (anemia, bleeding, fever).

— Hypotension if hemorrhagic shock or sepsis — check orthostatics if stable.

— Fever (>38.3°C) — assume neutropenic fever and treat empirically even before ANC returns.

— Hypoxia — consider pulmonary hemorrhage, transfusion-related lung injury, or, once ATRA started, differentiation syndrome.

— Petechiae on dependent areas, ankles, palate.

— Ecchymoses in non-traumatic distributions.

— Wet purpura — blood blisters on buccal mucosa, a marker of imminent serious bleeding.

— Gingival oozing, conjunctival hemorrhage, prolonged bleeding at IV sites.

— Pallor of conjunctiva, nail beds.

— Leukemia cutis is rare in APL (more typical of monocytic AMLs).

— Fundoscopy: retinal hemorrhages, Roth spots.

— Any focal deficit, cranial nerve palsy, or altered mental status → emergent head CT.

— Gingival hyperplasia is uncommon in APL (contrast with AML M4/M5).

APL physical exam reflects marrow failure plus coagulopathy, with relatively less organomegaly than other leukemias.

Vital signs / hemodynamics:

Skin/mucosa (highest-yield system):

HEENT/Neuro:

Cardiopulmonary: Flow murmur of anemia; crackles if pulmonary hemorrhage or volume overload from transfusions.

Abdomen: Hepatosplenomegaly and lymphadenopathy are uncommon in APL — their presence should raise suspicion for ALL or non-APL AML.

CCS pearl: On a CCS case suggesting APL, order vitals q1h, neuro checks q2h, strict bleeding precautions, no IM injections, no rectal temps, hold antiplatelets/anticoagulants, soft toothbrush, and place patient on bleeding precautions in the order set before any procedure.

Key distinction: Bulky lymphadenopathy + mediastinal mass + high blast count points toward T-ALL, not APL. APL is the leukemia of bleeding without bulk.

Diagnostic Workup — Initial Labs and Imaging

— WBC: variable; low or normal in classic hypergranular APL; high (>10k) in microgranular M3v (poor prognosis).

— Hemoglobin: often 7–9 g/dL.

— Platelets: typically <50k, often <20k.

— Smear: hypergranular promyelocytes, bilobed/dumbbell nuclei, multiple Auer rods (faggot cells) — pathognomonic when present.

— PT and aPTT prolonged.

— Fibrinogen low (<150 mg/dL, often <100) — most sensitive marker.

— D-dimer markedly elevated.

— Thrombocytopenia.

— Together these define the APL coagulopathy: DIC + primary hyperfibrinolysis.

— BMP: assess for tumor lysis (↑K, ↑PO₄, ↑uric acid, ↓Ca, ↑Cr); LDH elevated.

— LFTs: baseline before ATRA/ATO (ATRA → hepatotoxicity; ATO → QT, hepatotoxicity).

— Mg, K — repleted aggressively before arsenic trioxide.

— Type and crossmatch (transfusions imminent).

— Blood cultures × 2, urinalysis, CXR if febrile.

— ECG with QTc measurement — baseline for ATO; goal QTc <460 ms before initiating.

— Pregnancy test in reproductive-age women.

— HIV, hepatitis B/C serologies (pre-chemo standard).

— Non-contrast head CT for any neuro symptom, headache, or altered mental status.

— CXR for dyspnea/hypoxia.

— Echo (LVEF) before anthracycline if used.

CBC with differential and peripheral smear — the single most important initial test.

Coagulation panel (mandatory, send STAT):

Chemistries:

Other initial:

Imaging:

Board pearl: A fibrinogen <150 with schistocytes absent in a leukemia workup strongly favors APL over TTP; APL's DIC is consumptive plus fibrinolytic, so D-dimer is disproportionately high and fibrinogen falls fast — recheck q6–12h during induction.

Diagnostic Workup — Confirmatory Studies

— Karyotype: t(15;17)(q24;q21) in ~95%.

— FISH for PML-RARA: rapid (hours), useful when karyotype delayed.

— RT-PCR for PML-RARA fusion transcript: gold standard; also establishes baseline transcript level for minimal residual disease (MRD) monitoring.

— Variant translocations (rare, ~5%): t(11;17) PLZF-RARA (ATRA-resistant — important to recognize), t(5;17), t(11;17) NuMA-RARA.

— CD33+ (bright), CD13+, MPO+ (strongly).

— HLA-DR negative, CD34 negative — the classic "DR-negative, CD34-negative" AML signature.

— Microgranular variant may show CD2 and CD34 positivity.

— Cytochemistry: myeloperoxidase strongly positive, Sudan black positive.

— Lumbar puncture: deferred until coagulopathy corrected and remission achieved; CNS involvement is uncommon at diagnosis in APL.

— Low risk: WBC ≤10,000 and platelets >40,000.

— Intermediate risk: WBC ≤10,000 and platelets ≤40,000.

— High risk: WBC >10,000 (regardless of platelets) — higher differentiation syndrome and early death risk.

Bone marrow aspirate and biopsy confirm AML (≥20% blasts/promyelocytes), but definitive APL diagnosis is genetic.

Cytogenetic and molecular confirmation:

Flow cytometry immunophenotype:

Other tests:

Risk stratification at diagnosis (Sanz score) — based on WBC and platelet count:

Key distinction: HLA-DR negative + CD34 negative + MPO bright + Auer rods/faggot cells → APL pattern. Any other AML is typically HLA-DR positive. This single immunophenotype can clinch suspicion within hours.

Step 3 management: Do not wait for PCR confirmation to start ATRA. Initiate ATRA at first morphologic or clinical suspicion; if molecular testing later returns negative, simply stop — ATRA exposure for 24–72h is well tolerated and the risk-benefit strongly favors empiric treatment.

Risk Stratification and First-Line Management Logic

— Low/intermediate risk (WBC ≤10k): ATRA + arsenic trioxide (ATO) — chemotherapy-free, ~95–98% cure.

— High risk (WBC >10k): ATRA + ATO + cytotoxic chemotherapy (idarubicin or gemtuzumab ozogamicin) — anthracycline added to control rapid proliferation.

— Platelet transfusion goal: maintain ≥30,000–50,000/µL (some guidelines push 50k during active bleeding).

— Fibrinogen goal: maintain ≥150 mg/dL with cryoprecipitate (each unit ↑ fibrinogen ~5–10 mg/dL; typical dose 10 units).

— PT/INR: correct with fresh frozen plasma if prolonged.

— Recheck CBC, fibrinogen, PT/PTT, D-dimer every 6–12 hours during induction.

— Avoid: antifibrinolytics (e.g., tranexamic acid) — controversial; not routine due to thrombosis risk; central lines, LPs, and biopsies until coagulopathy corrected when possible.

— Do NOT perform leukapheresis in APL — it worsens coagulopathy and increases bleeding death. (Major distinction from other AMLs.)

— Control WBC with ATRA + chemotherapy, not mechanical removal.

Once APL is suspected, management runs on three parallel tracks simultaneously: empiric ATRA, aggressive blood product support, and definitive risk-adapted induction.

Sanz risk stratification drives regimen choice:

Supportive care priorities (first 24–48 hours, the highest-mortality window):

Hyperleukocytosis management:

Tumor lysis prophylaxis: IV fluids, allopurinol; rasburicase if uric acid markedly elevated or G6PD non-deficient.

Board pearl: The two cardinal "do nots" of APL in the ED: (1) do not delay ATRA awaiting cytogenetics, (2) do not leukapherese. Both errors are repeatedly tested on Step 3.

CCS pearl: Order set should include "transfuse platelets to keep >30k, cryoprecipitate to keep fibrinogen >150, FFP for PT prolongation, q6h coags" as standing orders during induction.

Pharmacotherapy — First-Line Drug Regimen

— Mechanism: binds PML-RARA fusion protein, releases transcriptional repression, induces terminal differentiation of promyelocytes into mature neutrophils.

— Dose: 45 mg/m²/day PO divided BID until complete remission (typically 4–6 weeks).

— Onset of effect: coagulopathy begins improving within 2–5 days.

— Side effects: headache (pseudotumor cerebri, especially in pediatrics), dry skin/mucositis, hypertriglyceridemia, hepatotoxicity, differentiation syndrome, teratogenicity.

— Mechanism: binds PML moiety, degrades PML-RARA, induces apoptosis and partial differentiation.

— Dose induction: 0.15 mg/kg/day IV until remission.

— Side effects: QT prolongation (torsades risk), hepatotoxicity, differentiation syndrome, peripheral neuropathy, hyperleukocytosis.

— Monitoring: ECG at baseline and weekly; keep QTc <500 ms, K >4.0, Mg >1.8.

— Idarubicin 12 mg/m² IV on days 2, 4, 6, 8, or

— Gemtuzumab ozogamicin (anti-CD33 ADC) 6–9 mg/m² IV — preferred in older/comorbid patients to avoid anthracycline cardiotoxicity.

— Prednisone 0.5 mg/kg/day during induction, particularly if WBC rising or high-risk.

All-trans retinoic acid (ATRA / tretinoin):

Arsenic trioxide (ATO):

High-risk additions (WBC >10k):

Differentiation syndrome prophylaxis:

Consolidation: Multiple cycles of ATRA + ATO (low/intermediate risk) or ATRA + ATO + anthracycline (high risk).

Maintenance: Generally not required with modern ATRA + ATO regimens (contrast with older ATRA + chemo protocols, which used ATRA/6-MP/methotrexate maintenance for 1–2 years).

Step 3 management: Start ATRA + dexamethasone prophylaxis empirically at suspicion; add ATO once diagnosis confirmed and electrolytes/QTc optimized; chemotherapy reserved for high-risk WBC >10k or to control rapid leukocytosis.

Board pearl: APL is the paradigm of targeted, chemotherapy-free leukemia cure — ATRA + ATO achieves >95% long-term remission in low-risk disease, transforming the most lethal AML into the most curable.

Differentiation Syndrome — Recognition and Management

— Unexplained fever.

— Dyspnea, hypoxia.

— Weight gain >5 kg, edema.

— Pulmonary infiltrates on CXR (often bilateral, interstitial/alveolar).

— Pleural or pericardial effusion.

— Hypotension.

— Acute kidney injury.

— Rising WBC (often >10k) — leukocytosis is a major harbinger.

— Dexamethasone 10 mg IV q12h at the first sign — do not wait for full syndrome.

— Continue at least 3 days after symptoms resolve, then taper.

— Furosemide for volume overload.

— Hold ATRA/ATO temporarily only in severe DS (ICU-level respiratory or hemodynamic failure); resume after improvement.

— Supportive care: supplemental O₂, mechanical ventilation if needed, vasopressors.

— Prednisone 0.5 mg/kg/day during induction in high-risk patients (WBC >10k) or rising WBC.

Differentiation syndrome (DS), formerly "retinoic acid syndrome," is the most dangerous treatment complication of APL, occurring in 15–25% of patients receiving ATRA and/or ATO.

Pathophysiology: Differentiating promyelocytes release inflammatory cytokines (IL-1, IL-6, TNF) and express adhesion molecules → capillary leak, tissue infiltration, end-organ inflammation.

Timing: Usually within the first 1–3 weeks of induction (median day 7–11); bimodal peak at days 0–7 and 21–28.

Clinical features (≥2 of the following with no other explanation):

Management (memorize):

Prophylaxis:

Key distinction: DS vs pneumonia vs transfusion-associated circulatory overload (TACO) — DS is suggested by the constellation of fever + hypoxia + weight gain + effusions + rising WBC in a patient 1–3 weeks into ATRA/ATO, with no clear infectious source.

CCS pearl: Daily weights, strict I/Os, q8h vitals with SpO₂, daily CXR if symptomatic; threshold for dexamethasone should be very low — overtreatment is safer than missed DS, which carries ~10% mortality when delayed.

Special Populations — Elderly and Renal/Hepatic Impairment

— APL outcomes in older adults have improved dramatically with ATRA + ATO, which avoids anthracycline cardiotoxicity.

— Even in patients >70 years, ATRA + ATO yields 5-year survival ~80%, compared to ~40% with traditional chemo-based regimens.

— Avoid idarubicin if LVEF <50%, prior anthracycline exposure, or significant cardiac history → use gemtuzumab ozogamicin as the cytoreductive agent in high-risk older patients.

— Closer QTc monitoring during ATO — older patients often on QT-prolonging drugs (amiodarone, citalopram, ondansetron, fluoroquinolones).

— More vigilant infection surveillance — baseline immune senescence + neutropenia.

— ATRA: primarily hepatic metabolism; no dose adjustment needed for renal impairment.

— ATO: ~15% renal excretion; caution with CrCl <30 mL/min, consider 50% dose reduction; monitor arsenic levels if available.

— Avoid nephrotoxins (aminoglycosides, IV contrast, NSAIDs) during induction.

— Aggressive tumor lysis prophylaxis — AKI further restricts options.

— Both ATRA and ATO are hepatotoxic; check LFTs 2–3× weekly during induction.

— Hold ATRA/ATO if transaminases >5× ULN or bilirubin >3× ULN; restart at reduced dose once normalized.

— Differentiation syndrome can independently cause hepatic dysfunction — distinguish by clinical context.

— Cardiac: baseline ECG, echo; avoid idarubicin if EF reduced.

— Diabetes: steroid-induced hyperglycemia common during DS prophylaxis/treatment.

— Anticoagulation: hold all antiplatelets and anticoagulants during active coagulopathy; resume cautiously once remission achieved.

Elderly patients (>60–70 years):

Renal impairment:

Hepatic impairment:

Comorbidity-driven adjustments:

Step 3 management: In an elderly APL patient with reduced EF and high-risk WBC, the optimal regimen is ATRA + ATO + gemtuzumab ozogamicin rather than ATRA + ATO + idarubicin — same efficacy, far less cardiotoxicity.

Board pearl: Age alone is not a contraindication to curative APL therapy — even septuagenarians achieve durable remission with ATRA + ATO. Reserve palliative-only approaches for true frailty or end-stage organ failure.

Special Populations — Pregnancy and Pediatrics

— ATRA is teratogenic (FDA category D) — causes retinoid embryopathy (CNS, craniofacial, cardiac, thymic defects). Contraindicated in first trimester.

— ATO is also teratogenic and embryotoxic — contraindicated throughout pregnancy.

— First trimester APL diagnosis:

— Discuss therapeutic abortion vs delayed treatment (rarely feasible — APL is too acute).

— If pregnancy continued: anthracycline-based chemotherapy (daunorubicin) without ATRA until second trimester; high fetal risk.

— Second/third trimester:

— ATRA can be used (relatively safer after organogenesis); add anthracycline if needed.

— Avoid ATO entirely throughout pregnancy.

— Plan delivery once coagulopathy resolved; coordinate hematology + MFM + neonatology.

— Postpartum: Standard ATRA + ATO regimen; no breastfeeding (drug excretion).

— APL accounts for ~5–10% of pediatric AML.

— Same PML-RARA biology; ATRA + ATO is now standard, replacing older ATRA + chemo regimens.

— Pseudotumor cerebri is more common in children on ATRA — monitor for headache, vomiting, papilledema; treat with dose reduction + acetazolamide.

— Growth, fertility, and late cardiac effects favor chemotherapy-free regimens when possible.

— Hyperleukocytosis is more common in pediatric APL → higher DS risk; prophylactic steroids routine.

— Reproductive-age women on ATRA require two forms of effective contraception during therapy and for 1 month after discontinuation.

— Men: barrier contraception during therapy; fertility preservation discussion before chemotherapy.

Pregnancy:

Pediatrics:

Contraception counseling:

Key distinction: Pregnancy + new pancytopenia + DIC is not HELLP if there are circulating promyelocytes with Auer rods — peripheral smear is decisive.

Step 3 management: Pregnant patient, 28 weeks, new APL → ATRA + daunorubicin, hold ATO, deliver near term once coagulopathy resolved, then complete consolidation with ATRA + ATO postpartum.

Complications and Adverse Outcomes

— Intracranial hemorrhage (~60% of early deaths).

— Pulmonary hemorrhage, GI hemorrhage.

— Risk factors: WBC >10k, age >60, delayed ATRA, creatinine elevated, prolonged PT, low fibrinogen.

— Despite modern therapy, early death rate remains ~10–15% in real-world cohorts (vs <5% in trials) — reflects pre-hospital delays.

— Underappreciated — APL patients have simultaneous bleeding and thrombotic risk.

— DVT/PE, catheter thrombosis, MI, stroke can occur during induction.

— Avoid prophylactic anticoagulation during severe coagulopathy; reassess once fibrinogen and platelets stabilize.

— Neutropenic fever — empiric cefepime or pip-tazo; add vancomycin for line/skin source; antifungal (voriconazole, micafungin) if prolonged fever.

— Reactivation of latent infections (HBV, HSV, VZV) — antiviral prophylaxis standard.

— Therapy-related MDS/AML (rare with ATRA + ATO; higher with anthracycline-containing regimens).

— Cardiotoxicity from anthracyclines.

— Secondary malignancies.

Early hemorrhagic death (days 0–30) — the dominant killer:

Differentiation syndrome (see chunk 8) — second leading cause of induction morbidity.

Thrombosis:

Infection:

QT prolongation / torsades from ATO — fatal if K/Mg not maintained.

Pseudotumor cerebri from ATRA — headache, vomiting, vision changes; LP confirms ↑opening pressure; treat with acetazolamide ± dose reduction.

Hepatotoxicity from ATRA and ATO — usually reversible.

Hyperleukocytosis paradox: WBC may rise after ATRA starts (differentiating cells flood circulation) — this is expected, not treatment failure; manage with steroids and continue ATRA.

Late complications:

Relapse: ~5–10% with modern regimens; CNS relapse possible — salvage with ATO ± ATRA + autologous SCT if PCR-negative, or allogeneic SCT if persistent MRD.

Board pearl: Rising WBC on day 3–5 of ATRA is differentiation, not progression — continue therapy, add steroids, do not leukapherese.

When to Escalate Care — ICU, Consult, and Triage

— Start ATRA before transfer (it's oral, easy, life-saving).

— Transfer with active platelet and cryoprecipitate transfusion in progress.

— Avoid ground transport if hemodynamically unstable; air transport with blood products on board.

— Receiving center: tertiary academic hospital with hematology, blood bank, ICU, and ideally cytogenetics on site.

— Active major bleeding (intracranial, pulmonary, GI requiring vasopressors).

— Differentiation syndrome with respiratory failure or hemodynamic instability.

— Hyperleukocytosis with WBC >50k and end-organ dysfunction.

— Tumor lysis with AKI requiring renal replacement.

— QTc >500 ms on ATO requiring telemetry and electrolyte aggression.

— Sepsis/septic shock in neutropenic patient.

— Telemetry, daily CBC + coags q6–12h initially, daily LFTs, ECG with QTc 2–3×/week.

— Bleeding precautions, no IM injections, no rectal exams/temps, soft toothbrush, stool softeners.

— Hematology/oncology (primary).

— Blood bank (transfusion plan).

— Cardiology if EF reduced or QTc borderline.

— MFM if pregnant.

— Social work, palliative care for symptom management and family support.

— Fertility preservation (before chemo if time allows — but should not delay induction).

APL diagnosis or strong suspicion = immediate hematology/oncology consultation, even at 3 AM. Time-to-ATRA is the strongest modifiable predictor of survival.

Transfer criteria if at a community ED without heme/onc capability:

ICU admission criteria:

Floor-level admission (typical low-risk APL):

Consults to order at admission:

CCS pearl: On a Step 3 CCS case, the correct early sequence is: ATRA → CBC/coags/type & cross → platelet + cryo + FFP → heme/onc consult → admit to monitored bed → bone marrow biopsy and PML-RARA PCR → start ATO once QTc and electrolytes optimized. Skipping ATRA to "wait for confirmation" is a scored error.

Key Differentials — Other Acute Leukemias

— AML M4/M5 (monocytic): gingival hyperplasia, leukemia cutis, CNS involvement, high WBC — but HLA-DR positive and lacks t(15;17).

— AML M2 with t(8;21): Auer rods present but no severe DIC, generally favorable prognosis with standard "7+3."

— AML with inv(16): eosinophilic differentiation, favorable.

— Distinguishing feature: Non-APL AMLs generally lack the catastrophic coagulopathy and respond to leukapheresis in hyperleukocytosis — opposite of APL.

— More common in children; mediastinal mass (T-ALL), lymphadenopathy, hepatosplenomegaly, bone pain.

— TdT positive, CD19/CD10/CD22 (B-ALL) or CD3/CD7 (T-ALL) — distinct immunophenotype.

— Coagulopathy less severe; tumor lysis more prominent.

— Prior CML history, splenomegaly, t(9;22) BCR-ABL Philadelphia chromosome.

— Blast crisis can be myeloid or lymphoid; treat with TKI ± chemotherapy.

— Older patient, prior cytopenia history, dysplastic features on smear; less DIC.

— Pancytopenia without circulating blasts, hypocellular marrow, no Auer rods.

— May have bleeding but lacks DIC pattern.

— (1) Severe coagulopathy with low fibrinogen and high D-dimer at presentation,

— (2) HLA-DR negative + CD34 negative immunophenotype,

— (3) t(15;17) / PML-RARA fusion.

Acute myeloid leukemia, non-APL subtypes:

Acute lymphoblastic leukemia (ALL):

Chronic myeloid leukemia in blast crisis:

Myelodysplastic syndrome transforming to AML:

Aplastic anemia:

Key distinction: The triumvirate that distinguishes APL from all other acute leukemias:

Board pearl: If a question stem mentions "faggot cells" or "bundles of Auer rods" in a young adult with bleeding gums and prolonged PT/PTT, the answer is APL with ATRA initiation, regardless of what else is offered.

Key Differentials — Non-Leukemic Causes

— Identifiable infectious source, positive cultures, often gram-negative bacteremia.

— DIC labs similar (low fibrinogen, high D-dimer) but no circulating blasts.

— Treat underlying infection.

— Pentad: MAHA, thrombocytopenia, fever, neuro changes, renal dysfunction.

— Schistocytes on smear, normal PT/PTT/fibrinogen, ADAMTS13 <10%.

— Treatment: plasma exchange + steroids + caplacizumab — platelets contraindicated unless life-threatening bleed.

— Key distinction: TTP has normal coags; APL has profoundly abnormal coags.

— Usually pediatric, post-diarrheal (STEC), Shiga toxin–associated.

— Renal failure dominant; normal coags.

— Isolated thrombocytopenia; normal hemoglobin, WBC, coags; no DIC.

— Treat with steroids, IVIG.

— Recent heparin exposure, thrombosis more than bleeding, 4T score, anti-PF4 antibody.

— Prolonged PT (more than PTT), normal fibrinogen, normal platelets, normal smear.

— Coagulopathy with low fibrinogen possible, but stigmata of cirrhosis, hyperbilirubinemia, hypoalbuminemia, ascites; no circulating blasts.

— Clinical context obvious.

— Multi-organ thrombosis, antibody profile, usually known autoimmune history.

Disseminated intravascular coagulation from sepsis:

Thrombotic thrombocytopenic purpura (TTP):

Hemolytic uremic syndrome (HUS):

Immune thrombocytopenia (ITP):

Heparin-induced thrombocytopenia (HIT):

Vitamin K deficiency / warfarin overdose:

Liver failure:

Severe trauma / massive transfusion coagulopathy:

Antiphospholipid syndrome catastrophic variant:

Step 3 management: When DIC + thrombocytopenia + anemia is the presentation, the fastest discriminator is the peripheral smear: blasts/promyelocytes → APL; schistocytes without blasts → TTP/DIC; normal RBC morphology + isolated platelet drop → ITP. Order smear before committing to a treatment pathway.

Board pearl: Never transfuse platelets reflexively in suspected TTP — but in suspected APL, platelet transfusion to >30–50k is mandatory and life-saving. The smear is the pivot.

Long-Term Plan, Maintenance, and Survivorship

— Low/intermediate risk: 2–4 cycles of ATRA + ATO over ~6–9 months.

— High risk: ATRA + ATO + anthracycline (or gemtuzumab) for consolidation.

— Goal: achievement of molecular remission (PCR-negative PML-RARA) in bone marrow.

— Generally omitted in modern ATRA + ATO regimens (low-risk disease) due to high cure rates without it.

— ATRA-based chemotherapy regimens historically included maintenance with ATRA + 6-mercaptopurine + methotrexate for 1–2 years — still used in some high-risk or resource-limited settings.

— RT-PCR for PML-RARA from bone marrow every 3 months for 2 years post-consolidation, then less frequently.

— Molecular relapse (rising PCR transcripts before clinical relapse) → preemptive salvage with ATO ± ATRA, often achieving second remission.

— ATO-based reinduction if not previously exposed or remote exposure.

— Achieve second molecular remission → autologous hematopoietic stem cell transplant.

— Persistent MRD → allogeneic HSCT.

— CNS relapse: intrathecal chemotherapy ± craniospinal irradiation.

— Cardiac: Echo every 1–2 years if anthracycline-exposed; lifelong CV risk modification.

— Endocrine: Thyroid function, fertility assessment, premature menopause counseling.

— Secondary malignancy surveillance: age-appropriate cancer screening; therapy-related MDS/AML risk.

— Bone health: DEXA if prolonged steroids; calcium, vitamin D.

— Psychosocial: depression, anxiety, post-treatment fatigue — refer to survivorship clinic.

— Post-chemo revaccination series (inactivated influenza, pneumococcal PCV20, Tdap, COVID).

— Live vaccines deferred 6+ months after immunosuppression.

Consolidation phase:

Maintenance therapy:

Minimal residual disease (MRD) monitoring:

Relapsed APL management:

Survivorship issues:

Vaccinations:

Step 3 management: A patient 1 year post-APL induction with rising PML-RARA PCR transcripts but no clinical symptoms requires preemptive ATO-based salvage — do not wait for hematologic relapse. Molecular monitoring is the entire point.

Follow-Up, Monitoring, and Counseling

— CBC with differential, coags (PT/PTT, fibrinogen, D-dimer) q6–12h until coagulopathy resolves, then daily.

— BMP, Mg, Phos, LFTs daily; uric acid during tumor lysis window.

— ECG with QTc at baseline, then 2–3×/week on ATO; daily if QTc borderline.

— Daily weights, strict I/Os, vital signs q4h with SpO₂.

— Daily neuro and skin/mucosa exam for bleeding.

— Bone marrow biopsy at day ~28 for remission assessment.

— Visit weekly during active treatment cycles.

— CBC, BMP, LFTs, Mg weekly; ECG with QTc before each ATO cycle and periodically.

— Surveillance for neuropathy (ATO), hypertriglyceridemia (ATRA), hepatotoxicity, infections.

— Bone marrow with PML-RARA PCR every 3 months × 2 years, then every 6 months × 1 year, then yearly.

— CBC every 1–3 months.

— Echo annually if anthracycline-exposed.

— Adherence: ATRA is oral — emphasize importance of every dose; missed doses risk relapse.

— Drug interactions: Avoid concurrent vitamin A supplements (additive toxicity), tetracyclines (pseudotumor risk), strong CYP3A inducers/inhibitors.

— Pregnancy prevention during and 1 month after ATRA.

— Sun protection — ATRA causes photosensitivity.

— When to call: new headache, visual changes, dyspnea, fever, bleeding, weight gain >2 kg/week, leg swelling.

— Lifestyle: smoking cessation, alcohol moderation (hepatotoxicity), exercise as tolerated, nutrition for marrow recovery.

— Disability paperwork for treatment phase (typically 6–9 months off work).

— Insurance authorization for ATO (high-cost specialty drug).

— Survivorship care plan handoff to primary care after 2 years remission.

Induction-phase monitoring (inpatient, daily–q6h):

Consolidation-phase monitoring (outpatient):

Post-consolidation surveillance:

Counseling priorities:

Vocational/social:

CCS pearl: Schedule the next bone marrow + PCR at 3 months before discharging the patient from the consolidation phase — failure to ensure MRD follow-up is the most common transition-of-care error in APL care.

Ethical, Legal, and Patient Safety Considerations

— APL patients are often consented to chemotherapy within hours of diagnosis while facing imminent death — capacity assessment must be documented even when time is short.

— If patient lacks capacity (intracranial hemorrhage, encephalopathy), use surrogate decision-maker per state hierarchy; document attempts to identify advance directives.

— Discuss fertility preservation even if it cannot be operationalized — failure to mention it is a documented source of post-treatment litigation in young adults.

— Ethically justified by the risk-benefit asymmetry: ATRA exposure for 24–72 hours is benign, while delayed treatment is frequently fatal.

— Document clinical reasoning in the chart: "smear and coagulopathy consistent with APL; empiric ATRA initiated pending PML-RARA confirmation."

— Pregnant patient with first-trimester APL faces maternal-fetal conflict; offer non-directive counseling on continuation vs termination; involve ethics committee and MFM.

— Highest-risk transition is ED → inpatient (delayed ATRA, missed coagulopathy) and inpatient → outpatient consolidation (missed MRD monitoring, ATO QT toxicity at home).

— Standardized handoff with explicit medication list, next PCR date, QTc baseline, contraception status, and red-flag symptoms reduces error.

— Verify ABO/Rh, use leukoreduced and irradiated products in immunocompromised patients to prevent transfusion-associated GVHD.

— CMV-safe blood for transplant candidates.

— Cancer registry reporting required in all 50 states.

— Occupational exposure history (benzene, prior chemo) may have workers' compensation implications.

— Delayed ATRA or inappropriate leukapheresis causing harm requires transparent disclosure to patient/family per institutional policy.

— ATO is expensive (~$50,000+ per cycle); financial counseling and patient assistance programs should be engaged at diagnosis to prevent treatment interruption.

Informed consent under duress:

Empiric ATRA without molecular confirmation:

Pregnancy ethics:

Transition-of-care risks (Step 3 favorite):

Patient safety in transfusion:

Mandatory reporting / public health:

Disclosure of medical errors:

Resource allocation:

Board pearl: A pregnant patient declining therapeutic abortion for first-trimester APL is competent to refuse even at risk to the fetus and herself; the role of the physician is informed counseling, not coercion. Document thoroughly.

High-Yield Associations and Rapid-Fire Facts

t(15;17)(q24;q21) → PML-RARA fusion — pathognomonic of APL.

Faggot cells / bundles of Auer rods → APL morphology.

HLA-DR negative + CD34 negative + MPO bright → APL immunophenotype.

DIC + hyperfibrinolysis → APL coagulopathy (vs pure DIC of sepsis).

Tissue factor + annexin II overexpression → mechanism of APL coagulopathy.

ATRA = differentiation agent, binds PML-RARA, releases maturation block.

ATO = degrades PML-RARA, induces apoptosis.

Differentiation syndrome: fever, hypoxia, weight gain, effusions, pulmonary infiltrates, AKI; treat with dexamethasone 10 mg IV q12h.

Sanz score: WBC and platelet count drive risk stratification.

High risk = WBC >10,000 — add anthracycline or gemtuzumab.

Do NOT leukapherese in APL — exacerbates coagulopathy.

Do NOT delay ATRA awaiting cytogenetic confirmation.

Platelets >30–50k, fibrinogen >150 — transfusion goals during induction.

t(11;17) PLZF-RARA variant → ATRA-resistant, poor prognosis.

Microgranular M3v → high WBC, scant granules, CD2/CD34 positive, easy to misdiagnose.

Therapy-related APL → prior topoisomerase II inhibitors (anthracyclines, etoposide) for breast cancer, lymphoma.

ATRA toxicities: headache (pseudotumor cerebri), dry skin, hypertriglyceridemia, hepatitis, teratogenicity (category D).

ATO toxicities: QT prolongation (torsades), hepatotoxicity, peripheral neuropathy.

PML-RARA PCR monitoring drives MRD assessment and preemptive salvage.

>95% cure with ATRA + ATO in low-risk APL — most curable AML.

Early death within 30 days is the principal limit on cure — ED recognition is everything.

Hispanic/Latino populations have higher APL incidence.

No mediastinal mass, no bulky lymphadenopathy — these argue against APL.

Pregnancy: ATRA contraindicated in 1st trimester; ATO contraindicated throughout.

Maintenance not required with ATRA + ATO regimens.

Board pearl: When the stem contains "promyelocytes, low fibrinogen, prolonged PT," the answer is start ATRA immediately — every other choice (transfer, await cytogenetics, leukapheresis) is wrong.

Board Question Stem Patterns

— 35-year-old woman with 2 weeks of fatigue and gingival bleeding; CBC shows WBC 3.2k, Hb 8.1, plt 22k; smear with hypergranular promyelocytes and Auer rods; PT prolonged, fibrinogen 95, D-dimer markedly elevated.

— Best next step: Initiate all-trans retinoic acid (ATRA) immediately, transfuse platelets and cryoprecipitate, send PML-RARA PCR. (Wrong answers: await cytogenetics, leukapheresis, heparin for DIC, plasma exchange.)

— APL patient day 8 of ATRA + ATO develops fever 38.7°C, dyspnea, 4 kg weight gain, bilateral pulmonary infiltrates, WBC risen to 18k.

— Best next step: Dexamethasone 10 mg IV q12h, continue ATRA/ATO unless severe respiratory failure. (Wrong: discontinue ATRA permanently, broad-spectrum antibiotics alone, leukapheresis, diuresis alone.)

— APL patient with WBC 65k; intern proposes leukapheresis.

— Best next step: Do not perform leukapheresis; continue ATRA + add chemotherapy/anthracycline + steroids; aggressive blood product support.

— 28-week pregnant woman with new APL.

— Best next step: ATRA + daunorubicin (ATO contraindicated); deliver near term once coagulopathy resolved; ATO-based consolidation postpartum.

— Suspected APL with t(11;17) PLZF-RARA on cytogenetics; no response to ATRA.

— Recognize: ATRA-resistant variant; treat with standard AML chemotherapy ± HSCT.

— Patient on ATO with QTc 510 ms.

— Best next step: Hold ATO, replete K to >4.0 and Mg to >1.8, review and stop other QT-prolonging drugs, resume ATO once QTc <460.

— Patient 18 months post-APL therapy with rising PML-RARA PCR.

— Best next step: Preemptive ATO-based salvage; if molecular remission achieved → autologous HSCT.

— Breast cancer survivor 2 years post-doxorubicin presents with new pancytopenia and DIC.

— Recognize: therapy-related APL from topoisomerase II inhibitor.

Stem 1 — Classic presentation:

Stem 2 — Differentiation syndrome:

Stem 3 — Hyperleukocytosis trap:

Stem 4 — Pregnancy:

Stem 5 — Variant translocation:

Stem 6 — QT prolongation on ATO:

Stem 7 — MRD relapse:

Stem 8 — Therapy-related:

Board pearl: The answer in nearly every APL stem is ATRA + supportive transfusion + heme/onc consult — pattern recognition over algorithmic deliberation.

One-Line Recap

Acute promyelocytic leukemia is the t(15;17) PML-RARA AML in which empiric ATRA started at first suspicion of pancytopenia plus DIC-pattern coagulopathy with hypergranular promyelocytes saves lives — combined with arsenic trioxide it cures over 95% of patients, but only if early hemorrhagic death is prevented through aggressive platelet and cryoprecipitate support, vigilance for differentiation syndrome, and avoidance of leukapheresis.

Recognition: Pancytopenia + bleeding + low fibrinogen + high D-dimer + faggot cells + HLA-DR negative immunophenotype → APL until proven otherwise; confirm with PML-RARA PCR/FISH but do not wait to act.

Immediate management: ATRA 45 mg/m²/day PO at suspicion; platelets to >30–50k, fibrinogen to >150 with cryoprecipitate, FFP for PT prolongation, q6–12h coag monitoring, bleeding precautions, no leukapheresis, no central lines if avoidable, no IM injections.

Definitive therapy: ATRA + arsenic trioxide for low/intermediate risk (chemo-free, >95% cure); add idarubicin or gemtuzumab ozogamicin if WBC >10k (high-risk Sanz); steroid prophylaxis for differentiation syndrome in high-risk patients.

Pitfalls Step 3 loves: Leukapheresis (wrong), delaying ATRA for cytogenetics (wrong), missing differentiation syndrome (fatal), ATO in pregnancy (contraindicated), failing to monitor QTc and electrolytes (causes torsades), skipping MRD PCR follow-up (misses preemptive salvage opportunity) — recognize these and the topic is mastered.